<DOC>
	<DOCNO>NCT00653302</DOCNO>
	<brief_summary>Primary objective : - Efficacy assessment percentage positive responder patient receive Lantus plus glucophage association . Positive responder patient define final value HbA1c &lt; 7 % and/or final decrease HbA1c &gt; 15 % compare basal value ( HbA1c final - HbA1c basal ) . Secondary objective : - Determination predictive criterion HbA1c final , - Determination predictive criterion weight variation , - Description glycemic therapeutic criterion group responder ( positive negative responder ) , - Assessment lipidic parameter accord HbA1c weight change study ( final value - basal value ) . Safety : - Adverse Event ( AE ) /Serious Adverse Event ( SAE ) assessment</brief_summary>
	<brief_title>Phenotype Evaluation Insulin Naive Patients Using Lantus ( Insulin Glargine )</brief_title>
	<detailed_description />
	<mesh_term>Insulin , Globin Zinc</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<mesh_term>Metformin</mesh_term>
	<mesh_term>Insulin Glargine</mesh_term>
	<criteria>Known type 2 diabetes least 2 year No history Ketoacidosis BMI &gt; 25 &amp; &lt; 35 kg/m2 Type 2 diabetes treat oral bi tritherapy least 6 month With insulin release stimulator : sulfonamide glinide maximal posology ( defined SmPC ) , metformin minimal posology 1700mg/day ( 1320 mg metformin ) , HbA1c &gt; = 7.5 &lt; 11 % 2 different dosage last year Type 1 diabetes Glucophage intolerability Pregnancy Breast feed Partial pancreatectomy Hypersensitivity insulin glargine excipient Renal failure creatinin &gt; 135 µmol/L male &gt; 110 µmol/L female patient Hepatitis transaminases &gt; 3ULN Preproliferative proliferative retinopathy Acute cardiovascular accident within last 6 month Previous treatment insulin within last 6 month randomization</criteria>
	<gender>All</gender>
	<minimum_age>30 Years</minimum_age>
	<maximum_age>69 Years</maximum_age>
	<verification_date>December 2008</verification_date>
</DOC>